IP Library Granted Patent US 11,097,011
Granted Patent B2
US 11,097,011 · App. 16/860,292 · Granted Aug 24, 2021

Peptide oligonucleotide conjugates

Inventors: Gunnar J. Hanson (Cambridge, MA); Ming Zhou (Cambridge, MA)
Assignee: Sarepta Therapeutics, Inc.
A61K47/645A61K47/18C07K7/06C07K7/08A61K38/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,097,011
App. No.
16/860,292
Granted
Aug 24, 2021
Kind
B2
Abstract

Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.

Claims (52)

1. A method of treating Duchenne Muscular Dystrophy in a subject in need thereof, comprising administering to the subject a peptide-oligonucleotide-conjugate of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

A’ is selected from —NHCH 2 C(O)N H 2 , —N(C 1-6 alkyl)CH 2 C(O)NH 2 ,

wherein R 5 is —C(O)(O-alkyl) x —OH, wherein x is 3-10 and each alkyl group is independently at each occurrence C 2-6 -alkyl, or R 5 is selected from —C(O)C 1-6 alkyl, trityl, monomethoxytrityl, —(C 1-6 -alkyl)R 6 , —(C 1-6 heteroalkyl)-R 6 , aryl-R 6 , heteroaryl-R 6 , —C(O)O—(C 1-6 alkyl)-R 6 , —C(O)O-aryl-R 6 , —C(O)O-heteroaryl-R 6 , and

wherein R 6 is selected from OH, SH, and NH 2 , or R 6 is O, S, or NH, covalently linked to a solid support;

each R 1 is independently selected from OH and —NR 3 R 4 , wherein each R 3 and R 4 are independently at each occurrence —C 1-6 alkyl;

each R 2 is independently selected from H, a nucleobase, and a nucleobase functionalized with a chemical protecting-group, wherein the nucleobase independently at each occurrence comprises a C 3-6 heterocyclic ring selected from pyridine, pyrimidine, triazinane, purine, and deaza-purine;

z is 8-40; and

E′ is selected from H, —C 1-6 alkyl, —C(O)C 1-6 alkyl, benzoyl, stearoyl, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl,

wherein

Q is —C(O)(CH 2 ) 6 C(O)—or —C(O)(CH 2 ) 2 S 2 (CH 2 ) 2 C(O)—,

R 7 is —(CH 2 ) 2 OC(O)N(R 8 ) 2 , wherein R 8 is —(CH 2 ) 6 NHC(═NH)NH 2 , and

R 11 is selected from OH and —NR 3 R 4 ,

wherein L is covalently linked by an amide bond to the carboxy-terminus of J, and L is

selected from —NH(CH 2 ) 1-6 C(O)—, —NH(CH 2 ) 1-6 C(O)NH(CH 2 ) 1-6 C(O)—, and

t is 4-9;

each J is independently at each occurrence selected from an amino acid of the structure

wherein:

r and q are each independently 0, 1, 2, 3, or 4; and

each R 9 is independently at each occurrence selected from H, an amino acid side-chain, and an amino acid side-chain functionalized with a chemical protecting-group,

wherein two or more amino acid side-chain groups of R 9 independently at each occurrence comprise a sulfur, wherein two of the sulfur atoms, together with the atoms to which they are attached, form the structure

wherein d is 0 or 1, and M is selected from:

wherein each R 10 is independently at each occurrence H or a halogen; and

G is covalently linked to the amino-terminus of J, and G is selected from

H, —C(O)C 1-6 alkyl, benzoyl, and stearoyl, and

wherein at least one of the following conditions is true:

1) A′ is

2) E′ is

or 3) E′ is

2. The method of claim 1 , wherein

A′ is selected from —N(C 1-6 -alkyl)CH 2 C(O)NH 2 ,

3. The method of claim 1 , wherein E′ is selected from H, —C(O)CH 3 , trityl, 4-methoxytrityl, benzoyl, stearoyl, and

4. The method of claim 1 , wherein A′ is

and E′ is selected from H, —C(O)CH 3 , trityl, 4-methoxytrityl, benzoyl, and stearoyl.

5. The method of claim 1 , wherein the peptide-oligonucleotide-conjugate of Formula I is a peptide-oligonucleotide-conjugate selected from:

6. The method of claim 1 , wherein the peptide-oligonucleotide-conjugate is of the formula (Ia) and R 5 is —C(O)(O—CH 2 CH 2 ) 3 OH.

7. The method of claim 1 , wherein the peptide-oligonucleotide-conjugate is of the formula (Ib) and E′ is selected from H, O 1-6 alkyl, —C(O)CH 3 , benzoyl, and stearoyl.

8. The method of claim 1 , wherein M is

9. The method of claim 1 , wherein J is independently selected from cysteine and arginine.

10. The method of claim 1 , wherein each R 1 is N(CH 3 ) 2 .

11. The method of claim 1 , wherein L is selected from glycine and

12. The method of claim 1 , wherein L is glycine.

13. The method of claim 1 , wherein G is H or —C(O)C H 3 .

14. The method of claim 1 , wherein G is —C(O)CH 3 .

15. The method of claim 1 , wherein d is 1.

16. The method of claim 1 , wherein

is selected from:

17. The method of claim 1 , wherein the peptide-oligonucleotide-conjugate is selected from:

wherein

G is selected from H and —C(O)CH 3 , and

E′ is selected from H and —C(O)CH 3 .

Assignments (2)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: HANSON, GUNNAR J.; ZHOU, MING
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 054047/0779 →
Continuity (4)
Continuation 15574734
Provisional Application 62337536 · May 17, 2016
Provisional Application 62163960 · May 19, 2015
Related Publication 20200254109A1 · Aug 13, 2020
Cited By (1)
US 12,239,715